Participated · Equity · Aug 2025

VentriJect's core product is the Seisomofit, a CE-marked medical device that uses seismocardiography to detect chest-wall vibrations and estimate VO2max. The system delivers an estimated VO2max in under three minutes without exercise and provides results to users through the VentriJect app. The company was founded in 2018 as a spinout from Aalborg University and had a commercialised product by 2021. VentriJect says its technology has both medical and fitness applications, which supported rapid expansion across multiple European markets and existing customers. It has signed distributors in Denmark, the Netherlands, Sweden, Switzerland and the UK, and is in final negotiations with several European healthcare providers. The company is also exploring US market entry to access over 55,000 health clubs and the world’s largest healthcare market. VentriJect completed a €1.7 million funding round to support further market expansion.